Your browser doesn't support javascript.
loading
Improved growth velocity of a patient with Noonan-like syndrome with loose anagen hair (NS/LAH) without growth hormone deficiency by low-dose growth hormone therapy.
Takasawa, Kei; Takishima, Shigeru; Morioka, Chikako; Nishioka, Masato; Ohashi, Hirofumi; Aoki, Yoko; Shimohira, Masayuki; Kashimada, Kenichi; Morio, Tomohiro.
Afiliação
  • Takasawa K; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Takishima S; Department of Pediatrics, Kawaguchi Municipal Medical Center, Kawaguchi, Japan.
  • Morioka C; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Nishioka M; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Ohashi H; Department of Pediatrics, Kawaguchi Municipal Medical Center, Kawaguchi, Japan.
  • Aoki Y; Division of Medical Genetics, Saitama Children's Medical Center, Saitama, Japan.
  • Shimohira M; Department of Medical Genetics, Tohoku University School of Medicine, Sendai, Japan.
  • Kashimada K; Department of Pediatrics, Kawaguchi Municipal Medical Center, Kawaguchi, Japan.
  • Morio T; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
Am J Med Genet A ; 167A(10): 2425-9, 2015 Oct.
Article em En | MEDLINE | ID: mdl-26096762
ABSTRACT
Noonan-like syndrome with loose anagen hair (NS/LAH; OMIM 607721) is caused by a heterozygous c.4A>G mutation in SHOC2. Most cases exhibit both growth hormone deficiency (GHD) and growth hormone insensitivity (GHI) and thus require a high dose of growth hormone (GH) therapy (e.g., 35-40 µg/kg/day). We report on a genetically diagnosed NS/LAH patient manifesting severe short stature (-3.85 SDs) with low serum level of IGF1, 30 ng/ml. The peak levels of GH stimulation tests were within the normal range, and GHI was not observed in the IGF1 generation test. However, with low-dose GH therapy (25 µg/kg/day) for two years, IGF1 level and height were remarkably improved (IGF1 117 ng/ml, height SDs -2.20 SDs). Further, catch-up of motor development and improvement of the proportion of extending limbs to trunk were observed (the Developmental Quotient score increased from 68 to 98 points, and the relative sitting height ratio decreased from 0.62 to 0.57). Our results suggest that endocrinological causes for short stature are variable in NS/LAH and that GH therapy should be considered as a possible treatment for delayed development in NS/LAH.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator de Crescimento Insulin-Like I / Hormônio do Crescimento / Peptídeos e Proteínas de Sinalização Intracelular / Síndrome dos Cabelos Anágenos Frouxos / Transtornos do Crescimento / Perda Auditiva Neurossensorial / Mutação / Síndrome de Noonan Limite: Child, preschool / Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator de Crescimento Insulin-Like I / Hormônio do Crescimento / Peptídeos e Proteínas de Sinalização Intracelular / Síndrome dos Cabelos Anágenos Frouxos / Transtornos do Crescimento / Perda Auditiva Neurossensorial / Mutação / Síndrome de Noonan Limite: Child, preschool / Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article